secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001628280-22-018242
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx sells up to $20M in tenapanor Japan royalties to HealthCare Royalty
---------------------------------------------------------------------------

- Up to $20M total: $10M upfront, $5M on Japan regulatory approval for hyperphosphatemia, $5M if net sales exceed target by end of 2025.
- Royalties stem from Ardelyx's License Agreement with Kyowa Kirin for tenapanor in Japan.
- Agreement includes customary covenants restricting sale, lien, or forgiveness of the royalty stream.
- Events of default allow HealthCare Royalty to claim indemnification up to a liability cap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022018242/0001628280-22-018242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022018242/ardx-20220629.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-018242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer